FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020522041> ?p ?o ?g. }

• W3020522041 abstract "Abstract Background The additional benefit of methotrexate (MTX) as a concomitant treatment in PsA has not been fully elucidated for TNF inhibitors (TNFi) and no real-world data on this currently exist for ustekinumab (UST). We investigated the additive effect of MTX on the ability to reach composite treatment targets beyond monotherapy with UST or TNFi, and the ability to improve patient-reported outcomes in a real-world clinical setting in 8 European countries. Methods The PsABio study (NCT02627768) evaluates persistence, effectiveness and tolerability of 1st, 2nd or 3rd-line UST or TNFi in patients with PsA. Proportions of patients reaching minimal disease activity (MDA)/very low disease activity (VLDA) and clinical Disease Activity in Psoriatic Arthritis (cDAPSA) low disease activity (LDA) or remission, as well as the patient acceptable symptom state (PASS; score ≤4) of the 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) were evaluated. Here we present 6-month follow-up data using intention to treat (ITT) analysis; patients who stopped/switched initial treatment were imputed as non-responders. The effect of MTX co-therapy was investigated within UST and TNFi cohorts, as well as between the cohorts, using multivariate logistic regression including interaction terms, and propensity score (PS) analysis to adjust for imbalanced, potentially prognostic, baseline covariates. Results Of 930 patients, data was available for 868 ITT patients, including patients who switched/stopped before 6 months (UST: n = 28/426 [6.6%], TNFi: n = 44/442 [10.0%]). At baseline there were no relevant differences in demographics and disease activity, however there were significant differences in skin involvement as well as csDMARD and NSAID exposure. Co-therapy with MTX did not increase the likelihood of achieving any of the outcomes in either the UST or TNFi cohorts (Table 1). After PS adjustment, co-treatment with MTX did not influence treatment effects differently when added to UST compared with TNFi. concomitant use of csDMARDs other than MTX yielded very similar results. Conclusion In a real-world setting, concomitant treatment with MTX in addition to UST or TNFi was not associated with enhanced effects across a broad variety of disease outcomes, including disease activity, disease impact, and skin involvement within or between treatment cohorts, after PS adjustment for baseline confounders. Disclosures S. Siebert: Consultancies; AbbVie, UCB, Pfizer, Janssen, Boehringer Ingelheim, Celgene, Novartis. Grants/research support; Pfizer, Janssen, BMS, Celgene, UCB, Boehringer Ingelheim. E. Gremese: Consultancies; AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Sanofi, UCB, Roche, Pfizer. P. Bergmans: Shareholder/stock ownership; Johnson & Johnson. Other; Employee of Janssen. K. de Vlam: Consultancies; Johnson & Johnson. B. Joven-Ibáñez: Member of speakers’ bureau; Celgene, Novartis, MSD, Pfizer, AbbVie, Janssen. G. Katsifis: None. T.V. Korotaeva: Consultancies; Pfizer, MSD, Novartis, AbbVie, Celgene, Biocad, Janssen, UCB, Lilly, Novartis-Sandoz. W. Noël: Other; Employee of Janssen. C. Selmi: None. P.P. Sfikakis: None. P. Smirnov: Other; Employee of Janssen. E. Theander: Other; Employee of Janssen. M.T. Nurmohamed: Grants/research support; Pfizer, AbbVie, Roche, BMS, MSD, Mundipharma, UCB, Janssen, Menarini, Lilly, Sanofi, Celgene. L. Gossec: Honoraria; AbbVie, Celgene, Janssen, Lilly, Novartis-Sandoz, Pfizer, Sanofi, UCB. Grants/research support; Pfizer. J.S. Smolen: Consultancies; AbbVie, Amgen, AstraZeneca, Astro, Celgene, Celtrion, GlaxoSmithKline, ILTOO Pharma, Janssen, Lilly, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB. Grants/research support; AbbVie, Janssen, Lilly, MSD, Pfizer, Roche." @default.
• W3020522041 created "2020-05-01" @default.
• W3020522041 creator A5003030575 @default.
• W3020522041 creator A5007341235 @default.
• W3020522041 creator A5013138894 @default.
• W3020522041 creator A5028301750 @default.
• W3020522041 creator A5050924116 @default.
• W3020522041 creator A5054890385 @default.
• W3020522041 creator A5056428016 @default.
• W3020522041 creator A5057705176 @default.
• W3020522041 creator A5064804606 @default.
• W3020522041 creator A5066602987 @default.
• W3020522041 creator A5070120923 @default.
• W3020522041 creator A5085647114 @default.
• W3020522041 creator A5087471106 @default.
• W3020522041 creator A5090231742 @default.
• W3020522041 creator A5091895459 @default.
• W3020522041 date "2020-04-01" @default.
• W3020522041 modified "2023-10-01" @default.
• W3020522041 title "O24 Concomitant treatment with MTX does not increase the efficacy of ustekinumab or TFNi in PsA: results from the PsABio study" @default.
• W3020522041 doi "https://doi.org/10.1093/rheumatology/keaa110.023" @default.
• W3020522041 hasPublicationYear "2020" @default.
• W3020522041 type Work @default.
• W3020522041 sameAs 3020522041 @default.
• W3020522041 citedByCount "0" @default.
• W3020522041 crossrefType "journal-article" @default.
• W3020522041 hasAuthorship W3020522041A5003030575 @default.
• W3020522041 hasAuthorship W3020522041A5007341235 @default.
• W3020522041 hasAuthorship W3020522041A5013138894 @default.
• W3020522041 hasAuthorship W3020522041A5028301750 @default.
• W3020522041 hasAuthorship W3020522041A5050924116 @default.
• W3020522041 hasAuthorship W3020522041A5054890385 @default.
• W3020522041 hasAuthorship W3020522041A5056428016 @default.
• W3020522041 hasAuthorship W3020522041A5057705176 @default.
• W3020522041 hasAuthorship W3020522041A5064804606 @default.
• W3020522041 hasAuthorship W3020522041A5066602987 @default.
• W3020522041 hasAuthorship W3020522041A5070120923 @default.
• W3020522041 hasAuthorship W3020522041A5085647114 @default.
• W3020522041 hasAuthorship W3020522041A5087471106 @default.
• W3020522041 hasAuthorship W3020522041A5090231742 @default.
• W3020522041 hasAuthorship W3020522041A5091895459 @default.
• W3020522041 hasConcept C126322002 @default.
• W3020522041 hasConcept C151956035 @default.
• W3020522041 hasConcept C17923572 @default.
• W3020522041 hasConcept C1862650 @default.
• W3020522041 hasConcept C197934379 @default.
• W3020522041 hasConcept C203014093 @default.
• W3020522041 hasConcept C2776260265 @default.
• W3020522041 hasConcept C2777575956 @default.
• W3020522041 hasConcept C2778375690 @default.
• W3020522041 hasConcept C2778975655 @default.
• W3020522041 hasConcept C2779384505 @default.
• W3020522041 hasConcept C2780132546 @default.
• W3020522041 hasConcept C2780564577 @default.
• W3020522041 hasConcept C2781059491 @default.
• W3020522041 hasConcept C71924100 @default.
• W3020522041 hasConceptScore W3020522041C126322002 @default.
• W3020522041 hasConceptScore W3020522041C151956035 @default.
• W3020522041 hasConceptScore W3020522041C17923572 @default.
• W3020522041 hasConceptScore W3020522041C1862650 @default.
• W3020522041 hasConceptScore W3020522041C197934379 @default.
• W3020522041 hasConceptScore W3020522041C203014093 @default.
• W3020522041 hasConceptScore W3020522041C2776260265 @default.
• W3020522041 hasConceptScore W3020522041C2777575956 @default.
• W3020522041 hasConceptScore W3020522041C2778375690 @default.
• W3020522041 hasConceptScore W3020522041C2778975655 @default.
• W3020522041 hasConceptScore W3020522041C2779384505 @default.
• W3020522041 hasConceptScore W3020522041C2780132546 @default.
• W3020522041 hasConceptScore W3020522041C2780564577 @default.
• W3020522041 hasConceptScore W3020522041C2781059491 @default.
• W3020522041 hasConceptScore W3020522041C71924100 @default.
• W3020522041 hasLocation W30205220411 @default.
• W3020522041 hasOpenAccess W3020522041 @default.
• W3020522041 hasPrimaryLocation W30205220411 @default.
• W3020522041 hasRelatedWork W12158638 @default.
• W3020522041 hasRelatedWork W1605945 @default.
• W3020522041 hasRelatedWork W16769293 @default.
• W3020522041 hasRelatedWork W18303195 @default.
• W3020522041 hasRelatedWork W20072698 @default.
• W3020522041 hasRelatedWork W20510049 @default.
• W3020522041 hasRelatedWork W2344133 @default.
• W3020522041 hasRelatedWork W3090498 @default.
• W3020522041 hasRelatedWork W4835347 @default.
• W3020522041 hasRelatedWork W9050669 @default.
• W3020522041 isParatext "false" @default.
• W3020522041 isRetracted "false" @default.
• W3020522041 magId "3020522041" @default.
• W3020522041 workType "article" @default.